Rocuronium bromide (Org 9426) — Competitive Intelligence Brief

Rocuronium bromide (Org 9426) (Rocuronium bromide (Org 9426)) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Non-depolarizing neuromuscular blocking agent. Area: Anesthesiology.

phase 3 Non-depolarizing neuromuscular blocking agent Nicotinic acetylcholine receptor Anesthesiology Small molecule

Target snapshot

Rocuronium bromide (Org 9426) (Rocuronium bromide (Org 9426)) — Merck Sharp & Dohme LLC. Rocuronium bromide is a non-depolarizing neuromuscular blocking agent that competitively inhibits the nicotinic acetylcholine receptor at the neuromuscular junction.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Rocuronium bromide (Org 9426) TARGET	Rocuronium bromide (Org 9426)	Merck Sharp & Dohme LLC	phase 3	Non-depolarizing neuromuscular blocking agent	Nicotinic acetylcholine receptor
Succinylcholine Chloride	SUXAMETHONIUM	Novartis	marketed	Depolarizing Neuromuscular Blocker	Muscle-type nicotinic acetylcholine receptor	1952-01-01
Vecuronium + Atracurium	Vecuronium + Atracurium	Sir Ganga Ram Hospital	marketed	Neuromuscular blocking agent (non-depolarizing)	Nicotinic acetylcholine receptor at the neuromuscular junction
injection of NMBA	injection of NMBA	Fondation Ophtalmologique Adolphe de Rothschild	marketed	Neuromuscular blocking agent	Nicotinic acetylcholine receptor at neuromuscular junction
RSI succinylcholine	RSI succinylcholine	The University of Texas Health Science Center, Houston	marketed	Depolarizing neuromuscular blocking agent	Nicotinic acetylcholine receptor (neuromuscular junction)
Mailed nicotine replacement therapy	Mailed nicotine replacement therapy	Massachusetts General Hospital	marketed	Nicotine replacement therapy	Nicotinic acetylcholine receptors
Pre-Quit Nicotine Gum	Pre-Quit Nicotine Gum	University of Wisconsin, Madison	marketed	Nicotine replacement therapy	Nicotinic acetylcholine receptors

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Non-depolarizing neuromuscular blocking agent class)

1. University Hospital, Antwerp · 3 drugs in this class
2. Ain Shams University · 2 drugs in this class
3. Merck Sharp & Dohme LLC · 2 drugs in this class
4. Diskapi Yildirim Beyazit Education and Research Hospital · 1 drug in this class
5. Federal University of São Paulo · 1 drug in this class
6. Korea University Guro Hospital · 1 drug in this class
7. Assistance Publique Hopitaux De Marseille · 1 drug in this class
8. Ostfold Hospital Trust · 1 drug in this class
9. St. Antonius Hospital · 1 drug in this class
10. CHU de Reims · 1 drug in this class